Fab Protein

Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics

J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):204-213. doi: 10.1089/jop.2017.0063. Epub 2017 Nov 17.

ABSTRACT

PURPOSE: The nonclinical toxicology program described here was designed to characterize the safety profile of anti-factor D (AFD; FCFD4514S, lampalizumab) to support intravitreal (ITV) administration in patients with geographic atrophy (GA).